Key Takeaways:
- H1 revenue reached RMB 8.6 billion, up 45 percent year over year
- IFRS net profit of RMB 1.3 billion surpassed full-year 2025 total
- BD deals worth USD 34 billion signed over past 10 months
뒤로
Innovent Bio H1 profit rises 50% as product revenue jumps 57%
Innovent Biologics reported H1 2026 revenue of RMB 8.6 billion, up 45 percent year over year, with product revenue climbing 57 percent to RMB 8.2 billion.
"2026 marks Innovent's best strategic window to date," Dr. Michael Yu, founder, chairman and CEO of Innovent, said. "We have both the resolve and the confidence to drive our third critical transformation: evolving from a regional leading biopharmaceutical company into a global premier biopharma."
IFRS net profit reached RMB 1.3 billion, up 50.2 percent year over year, surpassing the full-year 2025 figure of RMB 814 million. Non-IFRS net profit rose 41 percent to RMB 1.7 billion. Gross margin held at 85 percent, with gross profit of RMB 7.3 billion, up 43 percent. The company held RMB 30.2 billion in cash as of July 31.
Shares surged 9.89 percent to HKD 110 in early Hong Kong trade on Wednesday, with turnover of HKD 316 million. The company targets RMB 20 billion in product revenue by 2027 and RMB 35-40 billion in total revenue by 2030.
Over the past 10 months, Innovent signed strategic collaborations with Takeda, Eli Lilly, Pfizer, Ollin and Spero covering more than 20 pipeline assets, including five co-development and co-commercialization programs. The aggregate deal value reached USD 34 billion, representing more than 30 percent of total out-licensing value among Chinese pharmaceutical companies over the same period.
Three late-stage global assets — IBI363 (PD-1/IL-2α-biased), IBI343 (CLDN18.2 ADC) and IBI324 (VEGF/ANG2) — have entered or are about to enter global multi-regional Phase 3 trials, with a combined addressable market estimated at over USD 60 billion. IBI363, co-developed with Takeda under the code TAK-928, targets a potential TAM of over USD 40 billion for its first wave of indications.
In oncology, the company is advancing an "IO + ADC" strategy with assets including IBI363, IBI343 and IBI3003 (GPRC5D/BCMA/CD3) in late-stage development. Through its collaboration with Lilly on Verzenio (abemaciclib) in breast cancer, Innovent gained entry into that high-incidence tumor type, complementing pipeline programs such as IBI354 (HER2 ADC) and IBI3014 (PD-L1/TROP2 ADC).
In general biomedicine, the company's four chronic disease franchises — metabolic, cardiovascular, ophthalmology and autoimmune — delivered strong performance. Key products include SYCUME (teprotumumab), the first new therapy for thyroid eye disease in China in 70 years; Mazdutide, the world's first approved GCG/GLP-1 dual-receptor agonist for obesity and type 2 diabetes; and SINTBILO (tafolecimab), the first China-domestic PCSK9 inhibitor on the NRDL.
R&D expenses reached RMB 1.7 billion in H1 2026, supporting systematic portfolio planning and globalization. The company has launched 20 products, with 13 listed on the NRDL.
The results mark a milestone for the company, which recorded a loss of RMB 95 million in H1 2024. Innovent's 2030 vision includes launching products in key European and US markets, with overseas product revenue beginning to contribute to overall performance. Investors will watch for progress on the three global Phase 3 programs and further BD announcements in the second half.
This article is for informational purposes only and does not constitute investment advice.
[1] INNOVENT BIO Surges ~10% in Early Trade as Interim Product Revenue Jumps 56.7%[2] Innovent Announces 2026 Interim Results and ... - Markets data[3] Innovent Biologics (1801) H1 2026 earnings summary[4] Innovent Announces 2026 Interim Results and Business ...[5] Innovent Bio's net profit in the first half of the year exceeded the full-year total for last year, with business development (BD) collaboration deals totaling nearly $34 billion over the past ten months.
